Ovarian Cancer

Protocol #SponsorProtocol Title

EMD Serono
EMR 100070-001, 2013-002834-19
A Phase I, Open-Label, Multiple-Ascending Dose Trial to Investigate the Safety, Tolerability, Pharmacokinetics, Biological and Clinical Activity of Avelumab (MSB0010718C) in Subjects with Metastatic or Locally Advanced Solid Tumors and Expansion to Selected Indications
B9991009, 2015-003091-77, JAVELIN OVARIAN 200
A Phase 3, Multi-Center, Randomized, Open-label Study Of Avelumab (MSB0010718C) Alone Or In Combination with Pegylated Liposomal Doxorubicin Versus Pegylated Liposomal Doxorubicin Alone In Patients with Platinum-Resistant/Refractory Ovarian Cancer

Northwest Georgia Oncology Centers‘ (NGOC) physicians work with gynecologic oncologists to provide expert care to patient with ovarian cancer.